

# SOLOMON ISLANDS

Number of new cases

**684**

Number of deaths


**365**

Number of prevalent cases (5-year)

**1 494**


## Statistics at a glance, 2022

	Males	Females	Both sexes
<b>Population</b>	366 698	354 466	721 164
<b>Incidence*</b>			
Number of new cancer cases	279	405	684
Age-standardized incidence rate	114.8	154.4	134.8
Risk of developing cancer before the age of 75 years (cum. risk %)	11.5	14.7	13.1
<b>Top 3 leading cancers (ranked by cases)**</b>	Prostate Liver Lung	Breast Cervix uteri Thyroid	Breast Prostate Cervix uteri
<b>Mortality*</b>			
Number of cancer deaths	166	199	365
Age-standardized mortality rate	70.8	78.4	74.6
Risk of dying from cancer before the age of 75 years (cum. risk %)	7.3	7.7	7.5
<b>Top 3 leading cancers (ranked by deaths)**</b>	Liver Prostate Lung	Breast Cervix uteri Ovary	Liver Breast Cervix uteri
<b>Prevalence*</b>			
5-year prevalent cases	539	955	1 494



## Top 5 most frequent cancers\*\*


**Males**



Rank	Cancer site	Number of cases	Percent
1st	Prostate	83	29.7%
2nd	Liver	40	14.3%
3rd	Lung	21	7.5%
4th	Leukaemia	16	5.7%
5th	NHL	9	3.2%
-	Others	110	39.4%

Number of new cases in 2022, males, all ages


**Females**



Rank	Cancer site	Number of cases	Percent
1st	Breast	129	31.9%
2nd	Cervix uteri	72	17.8%
3rd	Thyroid	38	9.4%
4th	Corpus uteri	28	6.9%
5th	Ovary	19	4.7%
-	Others	119	29.4%

Number of new cases in 2022, females, all ages

**Both sexes**



Rank	Cancer site	Number of cases	Percent
1st	Breast	129	18.9%
2nd	Prostate	83	12.1%
3rd	Cervix uteri	72	10.5%
4th	Liver	52	7.6%
5th	Thyroid	43	6.3%
-	Others	305	44.6%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Breast	129	1	18.9	5.2	51	2	14.0	2.2	315	88.9
Prostate	83	2	12.1	4.6	27	4	7.4	1.7	147	40.1
Cervix uteri	72	3	10.5	2.5	48	3	13.2	1.6	178	50.2
Liver	52	4	7.6	1.2	52	1	14.2	1.2	82	11.4
Thyroid	43	5	6.3	0.85	3	18	0.82	0.09	110	15.3
Lung	28	6	4.1	0.70	23	5	6.3	0.62	45	6.2
Corpus uteri	28	6	4.1	1.5	6	16	1.6	0.30	76	21.4
Leukaemia	24	8	3.5	0.26	13	6	3.6	0.20	62	8.6
Ovary	19	9	2.8	0.70	13	6	3.6	0.49	44	12.4
Colorectum	19	9	2.8	0.55	11	8	3.0	0.33	39	5.4
Lip, oral cavity	12	11	1.8	0.25	9	10	2.5	0.20	28	3.9
Oesophagus	11	12	1.6	0.13	11	8	3.0	0.13	16	2.2
NHL	11	12	1.6	0.13	9	10	2.5	0.11	31	4.3
Stomach	10	14	1.5	0.24	9	10	2.5	0.28	17	2.4
Salivary glands	7	15	1.0	0.10	7	13	1.9	0.10	17	2.4
Pancreas	7	15	1.0	0.14	7	13	1.9	0.14	5	0.69
Larynx	7	15	1.0	0.09	7	13	1.9	0.09	18	2.5
Bladder	6	18	0.88	0.17	2	19	0.55	0.08	16	2.2
Hodgkin lymphoma	6	18	0.88	0.04	0	26	0.00	0.00	18	2.5
Multiple myeloma	6	18	0.88	0.12	6	16	1.6	0.12	16	2.2
Testis	5	21	0.73	0.13	0	26	0.00	0.00	15	4.1
Penis	4	22	0.59	0.03	2	19	0.55	0.03	8	2.2
Kidney	3	23	0.44	0.03	0	26	0.00	0.00	9	1.3
Nasopharynx	2	24	0.29	0.05	2	19	0.55	0.05	5	0.69
Gallbladder	2	24	0.29	0.03	2	19	0.55	0.03	4	0.55
Brain CNS	2	24	0.29	0.03	2	19	0.55	0.03	6	0.83
Oropharynx	1	27	0.15	0.02	1	24	0.27	0.02	2	0.28
Melanoma	1	27	0.15	0.00	0	26	0.00	0.00	2	0.28
Vagina	1	27	0.15	0.03	1	24	0.27	0.03	2	0.56
Hypopharynx	0	30	0.00	0.00	0	26	0.00	0.00	0	0.00
Mesothelioma	0	30	0.00	0.00	0	26	0.00	0.00	0	0.00
Kaposi sarcoma	0	30	0.00	0.00	0	26	0.00	0.00	0	0.00
<b>All cancers</b>	<b>684</b>	-	-	<b>13.1</b>	<b>365</b>	-	-	<b>7.5</b>	<b>1 494</b>	-
<b>All cancers excl. NMSC</b>	<b>681</b>	-	-	<b>13.1</b>	<b>365</b>	-	-	<b>7.5</b>	<b>1 488</b>	-

## Data source and methods

### Incidence

**Country-specific data source:** No data  
**Method:** No data: the rates are those of neighbouring countries or registries in the same area

[Click here to see detailed data source and methods](#)



### Mortality

**Country-specific data source:** Survival estimates  
**Method:** Estimated from national incidence estimates by modelling, using mortality:incidence ratios derived from survival estimation

[Click here to see detailed data source and methods](#)

### Prevalence

Computed using sex-, site- and age-specific incidence to 1-,3- and 5-year prevalence ratios from Nordic countries for the period (2011-2020), and scaled using Human Development Index (HDI) ratios.



\* includes non-melanoma skin cancer (NMSC)  
 \*\* NMSC included in other cancers  
 Age standardization using world population ([see link](#))

## References

**Website citation**  
 Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

### Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2021 Feb 4. doi:10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. *Int J Cancer*. 2021 Apr 5. doi:10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

